Renaissance BioScience Corp., a global leader in yeast bioengineering, announced the appointment of Dr. James Tansey to its Board of Directors, effective immediately. Dr. Tansey brings extensive experience in life sciences, technology commercialization, and corporate governance, which is expected to bolster the company's strategic growth and global commercialization efforts.
Dr. Tansey is a serial entrepreneur and research academic who currently serves as a Professor at the University of British Columbia's Sauder School of Business. He previously held a faculty position at Oxford University's Saïd Business School. His entrepreneurial background includes being a member of the founding team at Gemina Labs, where he supports fundraising, business development, and shareholder strategy. Additionally, he serves on the boards of dynaCERT Inc. and Vanadium Resources Ltd., and is a Senior Advisor to InBC, British Columbia's $500 million strategic investment fund.
Maurice Boucher, Renaissance Co-Founder and Executive Chairman, expressed enthusiasm about the appointment, stating, "James brings an outstanding combination of entrepreneurial, strategic and governance experience, together with a strong track record of helping innovative technology companies grow." Boucher highlighted Tansey's focus on impact investing and environmental protection, noting that "this fits well with the positive environmental impact of Renaissance's technology platforms." Boucher added, "His expertise will be a valuable asset for Renaissance as we continue developing and globally commercializing our biotechnology platforms."
Dr. Tansey commented on his new role, saying, "Renaissance has developed an impressive portfolio of innovative technologies with significant commercial potential across agriculture, industrial biotechnology and animal and human health. I look forward to working with the Board and management team to help the company execute on its growth strategy and create long-term value."
Dr. John Husnik, Renaissance Co-Founder, Director and CSO, also welcomed Dr. Tansey, remarking, "His experience building companies, securing investment, and helping innovative technologies move toward commercialization will complement our scientific expertise and support Renaissance as we continue developing and expanding our leading technology platforms."
Renaissance BioScience Corp., based in Vancouver, Canada, is a global leader in yeast bioengineering, focusing on technology platforms of yeast-produced RNA and yeast-derived virus-like particles (VLPs). These platforms have initial applications in crop protection and future applications in animal and human health. The company develops innovative, market-ready, functional microorganisms that provide cost-effective solutions to environmental and industrial challenges in agriculture, food, nutrition, and health.
The appointment of Dr. Tansey signals a strategic move to strengthen the board's expertise in commercialization and impact investing, which could accelerate the company's path to market for its technologies. For more information about Renaissance BioScience, visit www.renaissancebioscience.com.
